Key organisational changes at Catalent's biologics business to meet customer demand for integrated and comprehensive end-to-end solutions
Catalent Pharma Solutions, provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has said it will reorganise its biologics business following its 2017 acquisition of Cook Pharmica and with it the addition of a 875,000 sq. ft facility in Bloomington, Indiana.
Tedd Green, former president of Cook Pharmica, will become senior VP of Catalent Biologics and will have responsibility for the entire biologics business. He will continue to report to Barry Littlejohns, president, Catalent Biologics and Specialty Drug Delivery and will also act as a member of Catalent’s executive Leadership Team. Green will be based at the Bloomington facility.
The position of VP and general manager of Drug Substance and Bioanalytical services for Catalent Biologics has been given to Mike Riley. He will lead the company’s biologics manufacturing business, including its mammalian cell-line engineering and biomanufacturing capabilities and its broad bioanalytical capabilities based at several sites across Catalent’s global network.
The new role of VP and general manager at Catalent Biologics Drug Product business has been assigned to Cory Lewis, who will focus on successfully growing the Catalent Biologics drug product offerings both in the US and in Europe.
Having been instrumental to its success through his contributions and leadership in the the last ten years, Ryan Hawkins has also been appointed as general manager of the Bloomington site.